NEW THERAPEUTIC STRATEGIES

Cindy NEUZILLET, M.D., Ph.D., H.D.R.
Institut Curie, Saint-Cloud

FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique

PDAC classifications: RNA

Collisson



Moffitt



Bailey



FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique

O'Kane et al., *Clin Cancer Res* 2020

PDAC classifications: RNA

Collisson



Moffitt



2 tumour subtypes
« classical » vs.
« basal »

Bailey



COMPASS study (N=195 RNAseq)







Not for routine clinical practice

O'Kane et al., *Clin Cancer Res* 2020

PACSign

Chemotherapy guided by RNA-based chimiogram

Sponsor: Curie Institute; PI: C. Neuzillet/J. Iovanna

Chemo-Pred test
(transcriptomic signature of sensitivity to each single drug)
Presentation of results for Patient X



sensitive | resistant | resistant | resistant | sensitive

FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique

PACSign

Chemotherapy guided by RNA-based chimiogram

Sponsor: Curie Institute; PI: C. Neuzillet/J. Iovanna

Chimiogram prediction (transcriptomic signature)

FOLFIRINOX sensitive if sensitive to ≥ 2/3 drugs (5FU, oxaliplatin, irinotecan)
Gem-nabP sensitive if sensitive to ≥ 1/2 drugs (gemcitabine, nab-paclitaxel)

Chemo-Pred test
(transcriptomic signature of sensitivity to each single drug)
Presentation of results for Patient X



sensitive | resistant | resistant | resistant | sensitive

FOLFIRINOX sensitive
Gem-nabP sensitive

FOLFIRINOX sensitive
Gem-nabP resistant

FOLFIRINOX resistant
Gem-nabP resistant

BRCA mutation
(regardless of transcriptomic signature)

FOLFIRINOX resistant
Gem-nabP sensitive

Statistical considerations (X. Paoletti):
ORR FOLFIRINOX=35%, ORR gemcitabine plus *nab*-paclitaxel=23%
p0=27%; p1=45%; alpha=beta=0.1 -> 49 evaluable patients + non-evaluable
–> total of **62 patients**

FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Geller et al., *Science* 2017







Nakano et al., *Medicine* 2020; Imai et al., *Cancer Manag Res* 2019; Mohindroo et al., *Cancer Med* 2020

AntibioPAC

Antibiotherapy with gemcitabine-based chemotherapy

Sponsor: Curie Institute; PI: C. Neuzillet



Supportive care
Malnutrition/sarcopenia

LOSS OF OPPORTUNITY!

- Impact on QoL
- Impact on survival
- Increased risk of post-operative complications
- Increased risk of toxicities of chemo / radiotherapy
- Increased risk of infections
- Increased care costs / length of stay
- Decrease in the efficacy of treatments

Hilmi et al., *Pharmacol Ther* 2018

Clinical trials

APACaP (advanced setting) - NCT02184663



APACaPOp PRODIGE 56 (adjuvant setting) - NCT03400072

FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique

ProActIF-01 study (PHRC-K 2020)

Randomized phase II study of evaluation of an individualized program of nutrition and adapted physical activity in frail patients with advanced lung or digestive cancer (ECOG PS 2 and/or malnourished)



FONDATION ARC POUR LA RECHERCHE SUR LE CANCER
Reconnue d'utilité publique